Claims for Patent: 11,116,742

Summary for Patent: 11,116,742

Title:	Methods of reducing the risk of cardiovascular events in a subject
Abstract:	In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Inventor(s):	Paresh Soni
Assignee:	Amarin Pharmaceuticals Ireland Ltd
Application Number:	US17/153,606
Patent Claims:	1. A method of reducing a risk of a cardiovascular event in a subject on statin therapy and with a prior percutaneous coronary intervention, the method comprising administering daily to the subject 4 g of eicosapentaenoic acid ethyl ester (E-EPA). 2. The method of claim 1, wherein the cardiovascular event is one or more of myocardial infarction, stroke, cardiovascular death, unstable angina, coronary revascularization, and/or hospitalizations for unstable angina. 3. The method of claim 1, wherein the subject has a baseline triglyceride level of at least 135 mg/dL. 4. The method of claim 1, wherein the E-EPA is present in a pharmaceutical composition and the E-EPA comprises at least about 90 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 5. The method of claim 4, wherein the E-EPA comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 6. The method of claim 5, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules. 7. The method of claim 1, wherein the subject has an established cardiovascular disease. 8. The method of claim 7, wherein the established cardiovascular disease is determined by the presence of any one of: documented coronary artery disease, documented cerebrovascular disease, documented carotid disease, documented peripheral arterial disease, or combinations thereof. 9. The method of claim 1, wherein the subject has diabetes and at least one additional risk factor for cardiovascular disease. 10. The method of claim 9, wherein the at least one additional risk factor for cardiovascular disease is selected from the group consisting of a subject (a) of male gender of at least 55 years of age or of female gender of at least 65 years of age, (b) who smokes cigarettes or has stopped smoking cigarettes within three months before administration of the E-EPA, (c) with blood pressure of at least 140 mmHg systolic or at least 90 mmHg diastolic, (d) on antihypertensive medication, (e) of male gender with HDL-cholesterol level 40 mg/dL or less or of female gender with HDL-cholesterol level 40 mg/dL or less, (f) who has an hsCRP level of greater than 3 mg/L, (g) who has a creatine clearance between 30 mL/min and 60 mL/min, (h) who has non-proliferative retinopathy, (i) who has pre-proliferative retinopathy, (j) who has proliferative retinopathy, (k) who has maculopathy, (l) who has advanced diabetic eye disease or a history of photocoagulation, (m) who has micro- or macro-albuminuria, and (n) who has an asymptomatic ankle-brachial index of less than 0.9.